CNS Pharmaceuticals (CNSP) Set to Post Quarterly Earnings on Wednesday

CNS Pharmaceuticals (NASDAQ:CNSP) will likely be releasing its Q3 2026 results on Wednesday, November 18th. Analysts expect CNS Pharmaceuticals to announce earnings of ($0.27) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

CNS Pharmaceuticals (NASDAQ:CNSP) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.14).

CNS Pharmaceuticals Trading Down 2.3%

Shares of NASDAQ CNSP opened at $3.85 on Wednesday. The stock has a 50 day moving average price of $5.11 and a 200 day moving average price of $4.51. CNS Pharmaceuticals has a 52-week low of $1.90 and a 52-week high of $10.54.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, CNS Pharmaceuticals presently has a consensus rating of “Sell”.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for primary and metastatic cancers of the central nervous system. The company is headquartered in Houston, Texas, and its shares trade on the Nasdaq Capital Market under the symbol CNSP. CNS Pharmaceuticals’ lead product candidate is berubicin, an anthracycline designed to cross the blood-brain barrier. The company is evaluating berubicin as a potential treatment for glioblastoma multiforme, an aggressive and often fatal form of brain cancer for which treatment options remain limited.